Advertisement

Cell Biochemistry and Biophysics

, Volume 71, Issue 2, pp 701–706 | Cite as

Hispidulin Enhances the Anti-Tumor Effects of Temozolomide in Glioblastoma by Activating AMPK

  • YanGang Wang
  • WeiPing Liu
  • XiaoSheng He
  • Zhou Fei
Original Paper

Abstract

Glioblastoma is an aggressive malignancy, which is notorious for its poor prognosis. Although Temozolomide (TMZ) has been showed to be an effective chemotherapeutic agent for glioblastoma treatment, the response rate is far from satisfactory. As a natural compound with anti-cancer activity against a variety of cancers, Hispidulin is a good candidate drug for combination therapy. This study is designed to determine whether Hispidulin could potentiate the anti-tumor activity of TMZ in glioblastoma. Cell proliferation and apoptosis were determined by MTT assay and Hoechst staining, respectively. Expression of proteins relevant to apoptosis and proliferation was detected by Western blotting. Our in vitro assays showed that Hispidulin enhanced the anti-tumor activity of TMZ in glioblastoma by both inhibiting cell proliferation and inducing cell apoptosis. The anti-tumor activity of Hispidulin and the enhanced TMZ anti-tumor activity by Hispidulin induced the activation of AMPK signaling pathway. Our results showed that Hispidulin, by activating AMPK, exhibited anti-tumor activity and potentiated the anti-tumor activity of TMZ in glioblastoma. Although further preclinical and clinical studies are needed, this study provides insight for using Hispidulin as a chemosensitizing agent in clinic settings.

Keywords

GBM TMZ Hispidulin AMPK 

References

  1. 1.
    Ostrom, Q. T., et al. (2013). CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncology, 15(Suppl 2), ii1–ii56.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Lin, G. S., et al. (2014). STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma. International Journal of Clinical and Experimental Pathology, 7(6), 3141–3149.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Stupp, R., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987–996.PubMedCrossRefGoogle Scholar
  4. 4.
    Quick, A., et al. (2010). Current therapeutic paradigms in glioblastoma. Reviews on Recent Clinical Trials, 5(1), 14–27.PubMedCrossRefGoogle Scholar
  5. 5.
    Chamberlain, M. C. (2010). Temozolomide: Therapeutic limitations in the treatment of adult high-grade gliomas. Expert Review of Neurotherapeutics, 10(10), 1537–1544.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang, J., Stevens, M. F., & Bradshaw, T. D. (2012). Temozolomide: Mechanisms of action, repair and resistance. Current Molecular Pharmacology, 5(1), 102–114.PubMedCrossRefGoogle Scholar
  7. 7.
    Tentori, L., & Graziani, G. (2009). Recent approaches to improve the antitumor efficacy of temozolomide. Current Medicinal Chemistry, 16(2), 245–257.PubMedCrossRefGoogle Scholar
  8. 8.
    Bourdillat, B., et al. (1988). Mechanism of action of hispidulin, a natural flavone, on human platelets. Progress in Clinical and Biological Research, 280, 211–214.PubMedGoogle Scholar
  9. 9.
    He, L., et al. (2011). Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3 K/Akt/mTOR signaling pathway. Cancer Science, 102(1), 219–225.PubMedCrossRefGoogle Scholar
  10. 10.
    Tan, R. X., et al. (1999). Mono- and sesquiterpenes and antifungal constituents from Artemisia species. Planta Medica, 65(1), 64–67.PubMedCrossRefGoogle Scholar
  11. 11.
    Yu, C. Y., et al. (2013). Potential Therapeutic Role of Hispidulin in Gastric Cancer through Induction of Apoptosis via NAG-1 Signaling. Evidence-Based Complementary and Alternative Medicine, 2013, 518301.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Gao, H., Wang, H., & Peng, J. (2014). Hispidulin induces apoptosis through mitochondrial dysfunction and inhibition of P13 k/Akt signalling pathway in HepG2 cancer cells. Cell Biochemistry and Biophysics, 69(1), 27–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Yang, J. M., et al. (2010). Hispidulin sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by AMPK activation leading to Mcl-1 block in translation. Journal of Agriculture and Food Chemistry, 58(18), 10020–10026.CrossRefGoogle Scholar
  14. 14.
    Lin, Y. C., et al. (2010). Hispidulin potently inhibits human glioblastoma multiforme cells through activation of AMP-activated protein kinase (AMPK). Journal of Agriculture and Food Chemistry, 58(17), 9511–9517.CrossRefGoogle Scholar
  15. 15.
    Cheng, H., et al. (2011). In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 67(3), 637–646.PubMedCrossRefGoogle Scholar
  16. 16.
    Huang, H., et al. (2011). Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Letters, 301(2), 221–228.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Chou, T. C., & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27–55.PubMedCrossRefGoogle Scholar
  18. 18.
    Kopelovich, L., et al. (2007). The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiology Biomarkers & Prevention, 16(7), 1330–1340.CrossRefGoogle Scholar
  19. 19.
    Garami, A., et al. (2003). Insulin activation of Rheb, a mediator of mTOR/S6 K/4E-BP signaling, is inhibited by TSC1 and 2. Molecular Cell, 11(6), 1457–1466.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang, J. F., et al. (2007). Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transplant Immunology, 17(3), 162–168.PubMedCrossRefGoogle Scholar
  21. 21.
    Romano, M. F., et al. (2004). Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. European Journal of Cancer, 40(18), 2829–2836.PubMedCrossRefGoogle Scholar
  22. 22.
    Yuan, Y., et al. (2012). Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neuroscience & Therapeutics, 18(7), 536–546.CrossRefGoogle Scholar
  23. 23.
    Gong, A., et al. (2014). Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. Cancer Chemotherapy and Pharmacology, 74(3), 531–538.PubMedCrossRefGoogle Scholar
  24. 24.
    Kunnumakkara, A. B., et al. (2008). Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clinical Cancer Research, 14(7), 2128–2136.PubMedCrossRefGoogle Scholar
  25. 25.
    Saha, A. K., et al. (2006). AMPK regulation of the growth of cultured human keratinocytes. Biochemical and Biophysical Research Communications, 349(2), 519–524.PubMedCrossRefGoogle Scholar
  26. 26.
    Motoshima, H., et al. (2006). AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer. Journal of Physiology, 574(Pt 1), 63–71.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Yu, S. Y., et al. (2009). Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase. Tumour Biology, 30(2), 80–85.PubMedCrossRefGoogle Scholar
  28. 28.
    Inoki, K., Zhu, T., & Guan, K. L. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115(5), 577–590.PubMedCrossRefGoogle Scholar
  29. 29.
    Wang, W., & Guan, K. L. (2009). AMP-activated protein kinase and cancer. Acta Physiologica (Oxf), 196(1), 55–63.CrossRefGoogle Scholar
  30. 30.
    Cheng, S. W., et al. (2004). Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. Journal of Biological Chemistry, 279(16), 15719–15722.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • YanGang Wang
    • 1
  • WeiPing Liu
    • 1
  • XiaoSheng He
    • 1
  • Zhou Fei
    • 1
  1. 1.Department of NeurosurgeryXijing Hospital of the Fourth Military Medical UniversityXi’anPeople’s Republic of China

Personalised recommendations